An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema (CONVERT II)

This is an open label, single arm study to evaluate the safety and effectiveness of the AeriSeal System to block collateral ventilation (CV). Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Chartis Pulmonary Assessment System. Subjects with CV- status will then undergo placement of Zephyr Valves in the target lobe for bronchoscopic lung volume reduction (BLVR) and be followed for 24 months.

Primary End-Point:
  • The percentage of study subjects that successfully convert from a positive collateral ventilation status (CV+) in the treated lobe to having little to no collateral ventilation (CV-) by Chartis.
ConvertII
Key inclusion criteria are:
  • Patients who are potential candidates for endobronchial valves with heterogeneous emphysema and collateral ventilation (CV+) as confirmed per the Chartis
ClinicalTrials.gov Identifier: NCT06035120

For more detailed information on this trial please click the link above to visit ClinicalTrials.gov

Thank You

For Contacting Us!

We’ll Respond to Your Message as Soon as Possible!